187 related articles for article (PubMed ID: 37013957)
21. Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans : A Retrospective Cohort Study.
Cohen JB; Cohen DL; Herman DS; Leppert JT; Byrd JB; Bhalla V
Ann Intern Med; 2021 Mar; 174(3):289-297. PubMed ID: 33370170
[TBL] [Abstract][Full Text] [Related]
22. A controlled trial of percutaneous adrenal arterial embolization for hypertension in patients with idiopathic hyperaldosteronism.
Zhou Y; Wang X; Hou J; Wan J; Yang Y; Liu S; Luo T; Liu Q; Xue Q; Wang P
Hypertens Res; 2024 Feb; 47(2):311-321. PubMed ID: 37644179
[TBL] [Abstract][Full Text] [Related]
23. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.
Laffin LJ; Rodman D; Luther JM; Vaidya A; Weir MR; Rajicic N; Slingsby BT; Nissen SE;
JAMA; 2023 Sep; 330(12):1140-1150. PubMed ID: 37690061
[TBL] [Abstract][Full Text] [Related]
24. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy.
Haase M; Riester A; Kröpil P; Hahner S; Degenhart C; Willenberg HS; Reincke M
J Clin Endocrinol Metab; 2014 Dec; 99(12):4397-402. PubMed ID: 25222758
[TBL] [Abstract][Full Text] [Related]
25. Nadir Aldosterone Levels After Confirmatory Tests Are Correlated With Left Ventricular Hypertrophy in Primary Aldosteronism.
Ohno Y; Sone M; Inagaki N; Kawashima A; Takeda Y; Yoneda T; Kurihara I; Itoh H; Tsuiki M; Ichijo T; Katabami T; Wada N; Sakamoto R; Ogawa Y; Yoshimoto T; Yamada T; Kawashima J; Matsuda Y; Kobayashi H; Kamemura K; Yamamoto K; Otsuki M; Okamura S; Izawa S; Okamoto R; Tamura K; Tanabe A; Naruse M;
Hypertension; 2020 Jun; 75(6):1475-1482. PubMed ID: 32248705
[TBL] [Abstract][Full Text] [Related]
26. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
[TBL] [Abstract][Full Text] [Related]
27. Personalized Treatment of Patients With Primary Aldosteronism.
Obeid H; Chen Cardenas SM; Khairi S; Turcu AF
Endocr Pract; 2023 Jun; 29(6):484-490. PubMed ID: 36273684
[TBL] [Abstract][Full Text] [Related]
28. Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism.
Haze T; Hirawa N; Yano Y; Tamura K; Kurihara I; Kobayashi H; Tsuiki M; Ichijo T; Wada N; Katabami T; Yamamoto K; Oki K; Inagaki N; Okamura S; Kai T; Izawa S; Yamada M; Chiba Y; Tanabe A; Naruse M
Atherosclerosis; 2021 May; 324():84-90. PubMed ID: 33831673
[TBL] [Abstract][Full Text] [Related]
29. Normokalemic hyperaldosteronism in patients with resistant hypertension.
Benchetrit S; Bernheim J; Podjarny E
Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
[TBL] [Abstract][Full Text] [Related]
30. Are there unknown mineralocorticoids in low-renin essential hypertension?
Hollifield JW; Slaton PE; Wilson HM; Sennett JA; Yarbro L; Island DP; Liddle GW
Mayo Clin Proc; 1977 May; 52(5):329-33. PubMed ID: 323587
[TBL] [Abstract][Full Text] [Related]
31. Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: a cohort study.
Köhler A; Sarkis AL; Heinrich DA; Müller L; Handgriff L; Deniz S; Schneider H; Künzel H; Ladurner R; Reincke M; Adolf C
Eur J Endocrinol; 2021 Oct; 185(5):663-672. PubMed ID: 34468397
[TBL] [Abstract][Full Text] [Related]
32. Importance of dietary salt restriction for patients with primary aldosteronism during treatment with mineralocorticoid receptor antagonists: The potential importance of post-treatment plasma renin levels.
Yoshida Y; Fujiki R; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Mori Y; Matsuda N; Noguchi T; Nakama H; Okamoto M; Gotoh K; Masaki T; Shibata H
Hypertens Res; 2023 Jan; 46(1):100-107. PubMed ID: 36229529
[TBL] [Abstract][Full Text] [Related]
33. Adrenal Vein Sampling Without Discontinuation of Mineralocorticoid Receptor Antagonist Therapy.
Ganesh M; Abadin SS; Fogelfeld L
Endocr Pract; 2020 Sep; 26(9):953-959. PubMed ID: 33471699
[TBL] [Abstract][Full Text] [Related]
34. Increased Dosage of MRA Improves BP and Urinary Albumin Excretion in Primary Aldosteronism With Suppressed Plasma Renin.
Saiki A; Otsuki M; Tamada D; Kitamura T; Mukai K; Yamamoto K; Shimomura I
J Endocr Soc; 2022 Jan; 6(1):bvab174. PubMed ID: 34909517
[TBL] [Abstract][Full Text] [Related]
35. Implication of MR Activity in Posttreatment Arterial Stiffness Reversal in Patients With Primary Aldosteronism.
Chen ZW; Pan CT; Liao CW; Tsai CH; Chang YY; Chang CC; Lee BC; Chiu YW; Huang WC; Wang SM; Lu CC; Chueh JS; Wu VC; Hung CS; Lin YH
J Clin Endocrinol Metab; 2023 Feb; 108(3):624-632. PubMed ID: 36333943
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers to Guide Medical Therapy in Primary Aldosteronism.
Hundemer GL; Leung AA; Kline GA; Brown JM; Turcu AF; Vaidya A
Endocr Rev; 2024 Jan; 45(1):69-94. PubMed ID: 37439256
[TBL] [Abstract][Full Text] [Related]
37. Long-term re-evaluation of primary aldosteronism after medical treatment reveals high proportion of normal mineralocorticoid secretion.
Lucatello B; Benso A; Tabaro I; Capello E; Caprino MP; Marafetti L; Rossato D; Oleandri SE; Ghigo E; Maccario M
Eur J Endocrinol; 2013 Apr; 168(4):525-32. PubMed ID: 23321497
[TBL] [Abstract][Full Text] [Related]
38. Preoperative mineralocorticoid receptor antagonist reduces postoperative hyperkalaemia in patients with Conn syndrome.
Zhang J; Libianto R; Lee JC; Grodski S; Shen J; Fuller PJ; Yang J
Clin Endocrinol (Oxf); 2022 Jan; 96(1):40-46. PubMed ID: 34743353
[TBL] [Abstract][Full Text] [Related]
39. Adrenal Ablation Versus Mineralocorticoid Receptor Antagonism for the Treatment of Primary Aldosteronism: A Single-Center Prospective Cohort Study.
Zhou Y; Liu Q; Wang X; Wan J; Liu S; Luo T; He P; Hou J; Pu J; Wang D; Liang D; Yang Y; Wang P
Am J Hypertens; 2022 Dec; 35(12):1014-1023. PubMed ID: 36205513
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of reduced mineralocorticoid receptor activation by unilateral adrenalectomy vs mineralocorticoid antagonist treatment in patients with primary aldosteronism - Implications for depression and anxiety.
Murck H; Adolf C; Schneider A; Schlageter L; Heinrich D; Ritzel K; Sturm L; Quinkler M; Beuschlein F; Reincke M; Künzel H
J Psychiatr Res; 2021 May; 137():376-382. PubMed ID: 33761426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
